Inhibitory effect of bilirubin on complement-mediated hemolysis

Area of Science:

• Immunology
• Biochemistry

Background:

• Bile pigments like unconjugated bilirubin (UB) are products of heme degradation.
• The complement (C) system is a crucial part of innate immunity, mediating inflammatory and cell-lytic responses.
• Understanding the interaction between bile pigments and the complement cascade is important for clinical conditions like hyperbilirubinemia.

Purpose of the Study:

• To investigate the in vitro effects of unconjugated bilirubin (UB) and bilirubin monoglucuronide (BMG) on the complement cascade.
• To identify the specific component(s) of the complement cascade most affected by UB.
• To elucidate the mechanism by which UB exerts its inhibitory action on the complement system.

Main Methods:

• In vitro assays measuring hemolytic activity of the classical complement pathway.
• Dose-response studies using varying concentrations of UB and BMG.
• Enzyme immunoassay to assess the binding of C1q to IgM and IgG in the presence of UB.

Main Results:

• Both UB and BMG demonstrated dose-dependent inhibition of classical pathway hemolysis at low micromolar concentrations.
• UB exhibited a stronger inhibitory effect than BMG.
• The C1 component of the complement cascade was most significantly inhibited by UB.
• UB was found to interfere with the binding of C1q to both human IgM and IgG.

Conclusions:

• Unconjugated bilirubin exerts an anti-complement effect primarily by inhibiting the C1 component, the recognition unit of the classical pathway.
• The inhibition of C1 is likely due to UB interfering with C1q binding to immune complexes (IgM and IgG).
• These findings suggest potential clinical implications for the role of bilirubin in hyperbilirubinemia and associated immune responses.